COVID-19 Impact on Global Benign Prostate Hyperplasia Drugs Market Size, Status and Forecast 2020-2026

August 2020 | 96 pages | ID: C91FFBD91424EN
QYResearch

Abstracts

This report focuses on the global Benign Prostate Hyperplasia Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Benign Prostate Hyperplasia Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Sanofi
• Coloplast
• Pfizer
• Merck
• GlaxoSmithKline
• Eli Lilly and Company
• Abbott Laboratories
• Teva Pharmaceuticals
• Allergan
• Boehringer Ingelheim

Market segment by Type, the product can be split into

• Alpha Blocker
• 5-Alpha Reductase Inhibitor
• Phosphodiesterase-5 Inhibitor
• Others

Market segment by Application, split into

• Hospital
• Clinic
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Benign Prostate Hyperplasia Drugs status, future forecast, growth opportunity, key market and key players.
• To present the Benign Prostate Hyperplasia Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Benign Prostate Hyperplasia Drugs are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Benign Prostate Hyperplasia Drugs Revenue
1.4 Market Analysis by Type
  1.4.1 Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Alpha Blocker
  1.4.3 5-Alpha Reductase Inhibitor
  1.4.4 Phosphodiesterase-5 Inhibitor
  1.4.5 Others
1.5 Market by Application
  1.5.1 Global Benign Prostate Hyperplasia Drugs Market Share by Application: 2020 VS 2026
  1.5.2 Hospital
  1.5.3 Clinic
  1.5.4 Other
1.6 Coronavirus Disease 2019 (Covid-19): Benign Prostate Hyperplasia Drugs Industry Impact
  1.6.1 How the Covid-19 is Affecting the Benign Prostate Hyperplasia Drugs Industry
    1.6.1.1 Benign Prostate Hyperplasia Drugs Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Benign Prostate Hyperplasia Drugs Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Benign Prostate Hyperplasia Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Benign Prostate Hyperplasia Drugs Market Perspective (2015-2026)
2.2 Benign Prostate Hyperplasia Drugs Growth Trends by Regions
  2.2.1 Benign Prostate Hyperplasia Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Benign Prostate Hyperplasia Drugs Historic Market Share by Regions (2015-2020)
  2.2.3 Benign Prostate Hyperplasia Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Benign Prostate Hyperplasia Drugs Market Growth Strategy
  2.3.6 Primary Interviews with Key Benign Prostate Hyperplasia Drugs Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Benign Prostate Hyperplasia Drugs Players by Market Size
  3.1.1 Global Top Benign Prostate Hyperplasia Drugs Players by Revenue (2015-2020)
  3.1.2 Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Players (2015-2020)
  3.1.3 Global Benign Prostate Hyperplasia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Benign Prostate Hyperplasia Drugs Market Concentration Ratio
  3.2.1 Global Benign Prostate Hyperplasia Drugs Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Benign Prostate Hyperplasia Drugs Revenue in 2019
3.3 Benign Prostate Hyperplasia Drugs Key Players Head office and Area Served
3.4 Key Players Benign Prostate Hyperplasia Drugs Product Solution and Service
3.5 Date of Enter into Benign Prostate Hyperplasia Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Type (2015-2020)
4.2 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Type (2021-2026)

5 BENIGN PROSTATE HYPERPLASIA DRUGS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
5.2 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Benign Prostate Hyperplasia Drugs Market Size (2015-2020)
6.2 Benign Prostate Hyperplasia Drugs Key Players in North America (2019-2020)
6.3 North America Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)
6.4 North America Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Benign Prostate Hyperplasia Drugs Market Size (2015-2020)
7.2 Benign Prostate Hyperplasia Drugs Key Players in Europe (2019-2020)
7.3 Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)
7.4 Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

8 CHINA

8.1 China Benign Prostate Hyperplasia Drugs Market Size (2015-2020)
8.2 Benign Prostate Hyperplasia Drugs Key Players in China (2019-2020)
8.3 China Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)
8.4 China Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Benign Prostate Hyperplasia Drugs Market Size (2015-2020)
9.2 Benign Prostate Hyperplasia Drugs Key Players in Japan (2019-2020)
9.3 Japan Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)
9.4 Japan Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size (2015-2020)
10.2 Benign Prostate Hyperplasia Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

11 INDIA

11.1 India Benign Prostate Hyperplasia Drugs Market Size (2015-2020)
11.2 Benign Prostate Hyperplasia Drugs Key Players in India (2019-2020)
11.3 India Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)
11.4 India Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Benign Prostate Hyperplasia Drugs Market Size (2015-2020)
12.2 Benign Prostate Hyperplasia Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020)
12.4 Central & South America Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Sanofi
  13.1.1 Sanofi Company Details
  13.1.2 Sanofi Business Overview and Its Total Revenue
  13.1.3 Sanofi Benign Prostate Hyperplasia Drugs Introduction
  13.1.4 Sanofi Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020))
  13.1.5 Sanofi Recent Development
13.2 Coloplast
  13.2.1 Coloplast Company Details
  13.2.2 Coloplast Business Overview and Its Total Revenue
  13.2.3 Coloplast Benign Prostate Hyperplasia Drugs Introduction
  13.2.4 Coloplast Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)
  13.2.5 Coloplast Recent Development
13.3 Pfizer
  13.3.1 Pfizer Company Details
  13.3.2 Pfizer Business Overview and Its Total Revenue
  13.3.3 Pfizer Benign Prostate Hyperplasia Drugs Introduction
  13.3.4 Pfizer Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)
  13.3.5 Pfizer Recent Development
13.4 Merck
  13.4.1 Merck Company Details
  13.4.2 Merck Business Overview and Its Total Revenue
  13.4.3 Merck Benign Prostate Hyperplasia Drugs Introduction
  13.4.4 Merck Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)
  13.4.5 Merck Recent Development
13.5 GlaxoSmithKline
  13.5.1 GlaxoSmithKline Company Details
  13.5.2 GlaxoSmithKline Business Overview and Its Total Revenue
  13.5.3 GlaxoSmithKline Benign Prostate Hyperplasia Drugs Introduction
  13.5.4 GlaxoSmithKline Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)
  13.5.5 GlaxoSmithKline Recent Development
13.6 Eli Lilly and Company
  13.6.1 Eli Lilly and Company Company Details
  13.6.2 Eli Lilly and Company Business Overview and Its Total Revenue
  13.6.3 Eli Lilly and Company Benign Prostate Hyperplasia Drugs Introduction
  13.6.4 Eli Lilly and Company Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)
  13.6.5 Eli Lilly and Company Recent Development
13.7 Abbott Laboratories
  13.7.1 Abbott Laboratories Company Details
  13.7.2 Abbott Laboratories Business Overview and Its Total Revenue
  13.7.3 Abbott Laboratories Benign Prostate Hyperplasia Drugs Introduction
  13.7.4 Abbott Laboratories Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)
  13.7.5 Abbott Laboratories Recent Development
13.8 Teva Pharmaceuticals
  13.8.1 Teva Pharmaceuticals Company Details
  13.8.2 Teva Pharmaceuticals Business Overview and Its Total Revenue
  13.8.3 Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Introduction
  13.8.4 Teva Pharmaceuticals Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)
  13.8.5 Teva Pharmaceuticals Recent Development
13.9 Allergan
  13.9.1 Allergan Company Details
  13.9.2 Allergan Business Overview and Its Total Revenue
  13.9.3 Allergan Benign Prostate Hyperplasia Drugs Introduction
  13.9.4 Allergan Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)
  13.9.5 Allergan Recent Development
13.10 Boehringer Ingelheim
  13.10.1 Boehringer Ingelheim Company Details
  13.10.2 Boehringer Ingelheim Business Overview and Its Total Revenue
  13.10.3 Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Introduction
  13.10.4 Boehringer Ingelheim Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020)
  13.10.5 Boehringer Ingelheim Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Benign Prostate Hyperplasia Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Benign Prostate Hyperplasia Drugs Revenue
Table 3. Ranking of Global Top Benign Prostate Hyperplasia Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Alpha Blocker
Table 6. Key Players of 5-Alpha Reductase Inhibitor
Table 7. Key Players of Phosphodiesterase-5 Inhibitor
Table 8. Key Players of Others
Table 9. COVID-19 Impact Global Market: (Four Benign Prostate Hyperplasia Drugs Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Benign Prostate Hyperplasia Drugs Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Benign Prostate Hyperplasia Drugs Players to Combat Covid-19 Impact
Table 14. Global Benign Prostate Hyperplasia Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Benign Prostate Hyperplasia Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Benign Prostate Hyperplasia Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Benign Prostate Hyperplasia Drugs Market Share by Regions (2015-2020)
Table 18. Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Benign Prostate Hyperplasia Drugs Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Benign Prostate Hyperplasia Drugs Market Growth Strategy
Table 24. Main Points Interviewed from Key Benign Prostate Hyperplasia Drugs Players
Table 25. Global Benign Prostate Hyperplasia Drugs Revenue by Players (2015-2020) (Million US$)
Table 26. Global Benign Prostate Hyperplasia Drugs Market Share by Players (2015-2020)
Table 27. Global Top Benign Prostate Hyperplasia Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostate Hyperplasia Drugs as of 2019)
Table 28. Global Benign Prostate Hyperplasia Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Benign Prostate Hyperplasia Drugs Product Solution and Service
Table 31. Date of Enter into Benign Prostate Hyperplasia Drugs Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US$)
Table 34. Global Benign Prostate Hyperplasia Drugs Market Size Share by Type (2015-2020)
Table 35. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Type (2021-2026)
Table 36. Global Benign Prostate Hyperplasia Drugs Market Size Share by Application (2015-2020)
Table 37. Global Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US$)
Table 38. Global Benign Prostate Hyperplasia Drugs Market Size Share by Application (2021-2026)
Table 39. North America Key Players Benign Prostate Hyperplasia Drugs Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)
Table 41. North America Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US$)
Table 42. North America Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)
Table 43. North America Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US$)
Table 44. North America Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)
Table 45. Europe Key Players Benign Prostate Hyperplasia Drugs Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)
Table 47. Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)
Table 49. Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)
Table 51. China Key Players Benign Prostate Hyperplasia Drugs Revenue (2019-2020) (Million US$)
Table 52. China Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)
Table 53. China Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US$)
Table 54. China Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)
Table 55. China Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US$)
Table 56. China Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)
Table 57. Japan Key Players Benign Prostate Hyperplasia Drugs Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)
Table 59. Japan Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)
Table 61. Japan Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Benign Prostate Hyperplasia Drugs Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)
Table 65. Southeast Asia Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)
Table 67. Southeast Asia Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)
Table 69. India Key Players Benign Prostate Hyperplasia Drugs Revenue (2019-2020) (Million US$)
Table 70. India Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)
Table 71. India Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US$)
Table 72. India Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)
Table 73. India Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US$)
Table 74. India Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Benign Prostate Hyperplasia Drugs Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Benign Prostate Hyperplasia Drugs Market Share (2019-2020)
Table 77. Central & South America Benign Prostate Hyperplasia Drugs Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Benign Prostate Hyperplasia Drugs Market Share by Type (2015-2020)
Table 79. Central & South America Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Benign Prostate Hyperplasia Drugs Market Share by Application (2015-2020)
Table 81. Sanofi Company Details
Table 82. Sanofi Business Overview
Table 83. Sanofi Product
Table 84. Sanofi Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US$)
Table 85. Sanofi Recent Development
Table 86. Coloplast Company Details
Table 87. Coloplast Business Overview
Table 88. Coloplast Product
Table 89. Coloplast Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US$)
Table 90. Coloplast Recent Development
Table 91. Pfizer Company Details
Table 92. Pfizer Business Overview
Table 93. Pfizer Product
Table 94. Pfizer Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US$)
Table 95. Pfizer Recent Development
Table 96. Merck Company Details
Table 97. Merck Business Overview
Table 98. Merck Product
Table 99. Merck Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US$)
Table 100. Merck Recent Development
Table 101. GlaxoSmithKline Company Details
Table 102. GlaxoSmithKline Business Overview
Table 103. GlaxoSmithKline Product
Table 104. GlaxoSmithKline Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US$)
Table 105. GlaxoSmithKline Recent Development
Table 106. Eli Lilly and Company Company Details
Table 107. Eli Lilly and Company Business Overview
Table 108. Eli Lilly and Company Product
Table 109. Eli Lilly and Company Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US$)
Table 110. Eli Lilly and Company Recent Development
Table 111. Abbott Laboratories Company Details
Table 112. Abbott Laboratories Business Overview
Table 113. Abbott Laboratories Product
Table 114. Abbott Laboratories Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US$)
Table 115. Abbott Laboratories Recent Development
Table 116. Teva Pharmaceuticals Business Overview
Table 117. Teva Pharmaceuticals Product
Table 118. Teva Pharmaceuticals Company Details
Table 119. Teva Pharmaceuticals Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US$)
Table 120. Teva Pharmaceuticals Recent Development
Table 121. Allergan Company Details
Table 122. Allergan Business Overview
Table 123. Allergan Product
Table 124. Allergan Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US$)
Table 125. Allergan Recent Development
Table 126. Boehringer Ingelheim Company Details
Table 127. Boehringer Ingelheim Business Overview
Table 128. Boehringer Ingelheim Product
Table 129. Boehringer Ingelheim Revenue in Benign Prostate Hyperplasia Drugs Business (2015-2020) (Million US$)
Table 130. Boehringer Ingelheim Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Benign Prostate Hyperplasia Drugs Market Share by Type: 2020 VS 2026
Figure 2. Alpha Blocker Features
Figure 3. 5-Alpha Reductase Inhibitor Features
Figure 4. Phosphodiesterase-5 Inhibitor Features
Figure 5. Others Features
Figure 6. Global Benign Prostate Hyperplasia Drugs Market Share by Application: 2020 VS 2026
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Other Case Studies
Figure 10. Benign Prostate Hyperplasia Drugs Report Years Considered
Figure 11. Global Benign Prostate Hyperplasia Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Benign Prostate Hyperplasia Drugs Market Share by Regions: 2020 VS 2026
Figure 13. Global Benign Prostate Hyperplasia Drugs Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Benign Prostate Hyperplasia Drugs Market Share by Players in 2019
Figure 16. Global Top Benign Prostate Hyperplasia Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostate Hyperplasia Drugs as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Benign Prostate Hyperplasia Drugs Revenue in 2019
Figure 18. North America Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Sanofi Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
Figure 27. Coloplast Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Coloplast Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
Figure 29. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Pfizer Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
Figure 31. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Merck Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
Figure 33. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. GlaxoSmithKline Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
Figure 35. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Eli Lilly and Company Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
Figure 37. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Abbott Laboratories Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
Figure 39. Teva Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Teva Pharmaceuticals Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
Figure 41. Allergan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Allergan Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
Figure 43. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Boehringer Ingelheim Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2015-2020)
Figure 45. Bottom-up and Top-down Approaches for This Report
Figure 46. Data Triangulation
Figure 47. Key Executives Interviewed